Seeking Alpha

Evans Capital

 
View as an RSS Feed
View Evans Capital's Comments BY TICKER:
Latest  |  Highest rated
  • Capitalizing On Cannabis: Key Considerations For Cannabis Stock Investors [View article]
    interesting your long MCIG but dont talk much about it. Tell us why you like that one. Thanks
    Jan 13 10:37 AM | 1 Like Like |Link to Comment
  • Capitalizing On Cannabis: Key Considerations For Cannabis Stock Investors [View article]
    good point on FSPM preferred shares. Fortunatley as you say the preferred are owned by the CEO. I dont think he would ever fall on his sword and completley dillute his own stock.
    Jan 13 09:31 AM | Likes Like |Link to Comment
  • Kandi Set To Surrender Gains Again [View article]
    Mr. Porcari, A quadruple in sales in a half of a year from 26 million to 100 million seems very hard to believe. You better hope you are right on that or your reputation will be forever ruined.
    Oct 1 12:40 PM | 2 Likes Like |Link to Comment
  • Lee Enterprises: A Grossly Undervalued News Company [View article]
    yeah dying industry. Thats why Buffett is buying all the newspaper companies up. Newspapers arent online or anything. No need for Online advertising!!! Cmon!
    Jun 19 04:45 PM | 1 Like Like |Link to Comment
  • Lee Enterprises: A Grossly Undervalued News Company [View article]
    your right, author doesnt really say how the 3.09 valuation is determined.

    That valuation is low in my opinion. Based off of MEG valuation, LEE should be trading at 5.33. Your research has LEE TTM free cash flow yield of 94% compaired to MEG 8.6%
    Jun 18 10:37 AM | 2 Likes Like |Link to Comment
  • Blast Off Time For Unilife [View article]
    Good job rehashing the conf call. Tell me something we dont already know!
    May 30 09:37 AM | Likes Like |Link to Comment
  • Why China Housing & Land Development Should Be Trading Substantially Higher [View article]
    Jtech - thanks for your comments. totally understand your compliance, as a money manager. agree china been taken out behind the woodshed.
    Apr 18 10:29 AM | Likes Like |Link to Comment
  • Why China Housing & Land Development Should Be Trading Substantially Higher [View article]
    what are the compliance issues? thanks
    Apr 17 04:17 PM | Likes Like |Link to Comment
  • Why China Housing & Land Development Should Be Trading Substantially Higher [View article]
    sounds good Jtechkid I will check it out. Why dont you write a seeking alpha article about EFUT?

    thanks
    Apr 17 02:04 PM | 1 Like Like |Link to Comment
  • Why China Housing & Land Development Should Be Trading Substantially Higher [View article]
    Your comment makes no sense. I get these numbers from the companys SEC filings. Can you explain why HGSH is valued so much higher than CHLN?
    Apr 17 09:20 AM | 4 Likes Like |Link to Comment
  • Implant Sciences: Final Piece Of The Puzzle In Place With TSA Approval [View article]
    Muktikat - did u listen to the Implant conference call last night? DMJR has been very cooperative working with Implant delaying the due date of the debt. DMJR was waiting for TSA approval. Now that IMSC has that, DMJR knows revenues will ramp and it will restructure the debt in their favor.

    Good try shorty. This is Invision all over again!
    Jan 17 05:44 PM | 2 Likes Like |Link to Comment
  • Adventrx Pharmaceuticals: Why It Is Worth Over $5 Per Share [View article]
    agree. I was in the queue to ask mangement on their protocol call why they felt the stock was trading at such a discount, but the call went to its time limit and my question never got asked.

    LONG
    Oct 31 09:53 AM | 1 Like Like |Link to Comment
  • Adventrx Pharmaceuticals: Why It Is Worth Over $5 Per Share [View article]
    Per their annual report, As of March 1, 2012, we have 14 employees. To improve efficencies they outsource most of their product development activites.
    Sep 27 09:28 AM | 1 Like Like |Link to Comment
  • Adventrx Pharmaceuticals: Why It Is Worth Over $5 Per Share [View article]
    My apologies your short position has not generated a profit on this "SA Pump" that moved the stock a whole 2.56% today.

    For your information Adventrx did not buy SythRx for "chicken feed" as their are large royalty payments due to SythRx investors based on the success of ANX-188. Here is a quote from CEO Brian Culley on what Adventrx has to offer to ANX-188 and what they are doing differently. - good luck to you.

    CEO Culley: "Sure. It's a colorful product. Because it has the ability to improve blood flow, one could apply it in a lot of different settings. A prior sponsor of this product tested it into phase III in sickle cell disease. Now they made a handful of mistakes. You know, to their credit it was the first large-scale sickle cell trial ever done so there were bound some things that didn't work out well for them. But they also didn't enroll the number of patients that they had planned to enroll and they had some, what I believe are, design flaws in the protocol. So although they had some things stacked against them, they very nearly succeeded. They did show a benefit. They did show that you could reduce the duration of crisis and they nearly showed statistical significance with that. It wasn't enough to get the product approved and in fact, it ended up being something that they were not able to go forward with.

    But for Adventrx, we feel that we are able to quite well define exactly what the errors were the first time it was tested. So we're looking to improve upon the original design. We've gone out into the community to find out what's changed since the study was done the first time so that we can do it and actually show that the benefit is statistically significant. So we're quite encouraged that the fact that there's been a demonstration that the drug is active and it has a benefit. But as it happens in clinical development, sometimes there are some mistakes that are made and I think we're going to be able to improve upon those. So we are now a vehicle for what I hope will be the final testing of this product in sickle cell disease patients."
    Sep 24 05:46 PM | 1 Like Like |Link to Comment
  • Adventrx Pharmaceuticals: Why It Is Worth Over $5 Per Share [View article]
    ?? the market cap of the company is only 38 million. My target is conservative. 665 million market cap would be $13 / share based on 49 million shares outstanding. whats not to get?
    Sep 24 04:15 PM | 1 Like Like |Link to Comment
COMMENTS STATS
78 Comments
26 Likes